

# Akintunde Bello

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11418384/publications.pdf>

Version: 2024-02-01

24  
papers

799  
citations

687363

13  
h-index

677142

22  
g-index

24  
all docs

24  
docs citations

24  
times ranked

975  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exposureâ€“Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1603-1613.	7.0	3
2	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. , 2022, 10, e004273.		10
3	Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants. <i>Clinical Pharmacology in Drug Development</i> , 2021, , .	1.6	3
4	Evaluation of Therapeutics for Severely Debilitating or Lifeâ€“Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 514-520.	4.7	3
5	A Machineâ€“Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 978-987.	4.7	23
6	Linking Tumor Growth Dynamics to Survival in Ipilimumabâ€“Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 825-834.	2.5	11
7	Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 705-715.	2.3	14
8	Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Timeâ€“Varying Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1018-1027.	4.7	15
9	Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma. , 2019, 7, 348.		17
10	Population Pharmacokinetics and Exposure â€” Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 364-373.	2.0	11
11	The Clinical Pharmacology of Elotuzumab. <i>Clinical Pharmacokinetics</i> , 2018, 57, 297-313.	3.5	7
12	An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab. <i>AAPS Journal</i> , 2017, 19, 557-567.	4.4	9
13	Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer. <i>Clinical Drug Investigation</i> , 2017, 37, 363-373.	2.2	19
14	Nivolumab Exposureâ€“Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5394-5405.	7.0	76
15	Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 243-257.	1.8	29
16	The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1441-1449.	1.9	29
17	Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 104-113.	2.0	36
18	Metabolism, excretion and pharmacokinetics of [ <sup>14</sup> C]crizotinib following oral administration to healthy subjects. <i>Xenobiotica</i> , 2015, 45, 45-59.	1.1	49

#	ARTICLE	IF	CITATIONS
19	Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1371-1377.	1.6	254
20	Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1252-1259.	4.1	84
21	Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4766-4777.	3.2	48
22	Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats. <i>Archives of Toxicology</i> , 2004, 78, 61-67.	4.2	9
23	Effects of the Des-F(6)-Quinolone Garenoxacin (BMS-284756), in Comparison to Those of Ciprofloxacin and Ofloxacin, on Joint Cartilage in Immature Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3320-3322.	3.2	25
24	Effect of a High-Fat Meal on the Pharmacokinetics of the Des-F(6)-Quinolone BMS-284756. <i>Pharmacotherapy</i> , 2002, 22, 160-165.	2.6	15